2025 Q4 -tulosraportti
Vain PDF
22 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 900 | - | - | ||
| 1 000 | - | - | ||
| 500 | - | - | ||
| 5 745 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenLooking forward to a bigger drop in the price this week! Everyone knows this one will go DOWN and by that I mean very DOWN and maybe as much as 1,- the question is just when, but it won't be long!!!!
·6 t sittenCan both shares and TR be traded worldwide? Thinking about the global interest in a week 😊💸
·6 t sittenCircio is indeed listed on oslo børs.. but as long as you have internet access, you can just sit in Malaysia and buy the dip if that's what you were wondering about?
·7 t sittenWHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
·8 t sittenJust a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
22 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenLooking forward to a bigger drop in the price this week! Everyone knows this one will go DOWN and by that I mean very DOWN and maybe as much as 1,- the question is just when, but it won't be long!!!!
- ·6 t sittenCan both shares and TR be traded worldwide? Thinking about the global interest in a week 😊💸·6 t sittenCircio is indeed listed on oslo børs.. but as long as you have internet access, you can just sit in Malaysia and buy the dip if that's what you were wondering about?
- ·7 t sittenWHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
- ·8 t sittenJust a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 900 | - | - | ||
| 1 000 | - | - | ||
| 500 | - | - | ||
| 5 745 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
22 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenLooking forward to a bigger drop in the price this week! Everyone knows this one will go DOWN and by that I mean very DOWN and maybe as much as 1,- the question is just when, but it won't be long!!!!
- ·6 t sittenCan both shares and TR be traded worldwide? Thinking about the global interest in a week 😊💸·6 t sittenCircio is indeed listed on oslo børs.. but as long as you have internet access, you can just sit in Malaysia and buy the dip if that's what you were wondering about?
- ·7 t sittenWHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
- ·8 t sittenJust a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 900 | - | - | ||
| 1 000 | - | - | ||
| 500 | - | - | ||
| 5 745 | - | - |
Välittäjätilasto
Dataa ei löytynyt